Changes in High-Density Lipoprotein Cholesterol and Risks of Cardiovascular Events: A Post Hoc Analysis from the PICASSO Trial

Authors
Eun-Jae LeeSun U. KwonJong-Ho ParkYong-Jae KimKeun-Sik HongSungwook YuYang-Ha HwangJi Sung LeeJuneyoung LeeJoung-Ho RhaSung Hyuk HeoSung Hwan AhnWoo-Keun SeoJong-Moo ParkJu-Hun LeeJee-Hyun KwonSung-Il SohnJin-Man JungHahn Young KimEung-Gyu KimSung Hun KimJae-Kwan ChaMan-Seok ParkHyo Suk NamDong-Wha Kang
Department
Dept. of Neurology (신경과학)
Issue Date
2020
Citation
Journal of Stroke, Vol.22(1) : 108-118, 2020
ISSN
2287-6405
Abstract
Background and purpose: Whether pharmacologically altered high-density lipoprotein cholesterol (HDL-C) affects the risk of cardiovascular events is unknown. Recently, we have reported the Prevention of Cardiovascular Events in Asian Patients with Ischaemic Stroke at High Risk of Cerebral Haemorrhage (PICASSO) trial that demonstrated the non-inferiority of cilostazol to aspirin and superiority of probucol to non-probucol for cardiovascular prevention in ischemic stroke patients (clinicaltrials.gov: NCT01013532). We aimed to determine whether on-treatment HDL-C changes by cilostazol and probucol influence the treatment effect of each study medication during the PICASSO study. Methods: Of the 1,534 randomized patients, 1,373 (89.5%) with baseline cholesterol parameters were analyzed. Efficacy endpoint was the composite of stroke, myocardial infarction, and cardiovascular death. Cox proportional hazards regression analysis examined an interaction between the treatment effect and changes in HDL-C levels from randomization to 1 month for each study arm. Results: One-month post-randomization mean HDL-C level was significantly higher in the cilostazol group than in the aspirin group (1.08 mmol/L vs. 1.00 mmol/L, P<0.001). The mean HDL-C level was significantly lower in the probucol group than in the non-probucol group (0.86 mmol/L vs. 1.22 mmol/L, P<0.001). These trends persisted throughout the study. In both study arms, no significant interaction was observed between HDL-C changes and the assigned treatment regarding the risk of the efficacy endpoint. Conclusions: Despite significant HDL-C changes, the effects of cilostazol and probucol treatment on the risk of cardiovascular events were insignificant. Pharmacologically altered HDL-C levels may not be reliable prognostic markers for cardiovascular risk.
Keywords
Cholesterol, HDLSecondary preventionCilostazolProbucolCholesterol ester transfer proteins
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/42554
Appears in Collections:
1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Neurology (신경과학)
Keimyung Author(s)
손성일
Full Text
https://www.j-stroke.org/journal/view.php?number=304
File in this Item
oak-2020-0014.pdf(1.55 MB)Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE